Perspective Perspectives are commissioned from an expert and discuss the clinical practice or public health implications of a published study. The original publication must be freely available online.

See all article types »

We Must Not Let Protestors Derail Trials of Pre-Exposure Prophylaxis for HIV

  • Joep M. A Lange
  • Published: July 19, 2005
  • DOI: 10.1371/journal.pmed.0020248

About the Author

Competing Interests

JMAL serves or has served on scientific (HIV) advisory boards and/or spoken at symposia of and/or received research grants from the following pharmaceutical companies: Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Idenix, Merck, Panacos, Pfizer, Roche, and Tibotec. He declares that he does not own any pharmaceutical company stock. He serves on the scientific advisory boards of the International AIDS Vaccine Initiative and the International Partnership for Microbicides, on the Global HIV Prevention Working Group of the Bill and Melinda Gates Foundation, and on the Strategic and Technical Advisory Committee for HIV/AIDS of the World Health Organization.